Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GT90001 + nivolumab
- Development stage
- Unknown
- Lead developer
- Kintor Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GT90001 + nivolumab is a combination therapy under investigation for advanced hepatocellular carcinoma (HCC). GT90001 (also known as PF-03446962) is a fully human monoclonal antibody targeting activin receptor-like kinase 1 (ALK-1), which inhibits ALK-1/TGF-β signaling and tumor angiogenesis. Nivolumab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2 to restore T-cell mediated anti-tumor immunity. The combination aims to enhance the efficacy of immune checkpoint inhibition in HCC by simultaneously inhibiting tumor angiogenesis and promoting immune response[1][2][3].
- Brand names
- Opdivo
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)ACVRL1 (Activin receptor-like kinase 1)
Beyond the preview
Go deeper on GT90001 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GT90001 + nivolumab.